SEARCH

SEARCH BY CITATION

References

  • Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 83, 20382044.
  • Bedi, A., Barber, J.P., Bedi, G.C., El-Deiry, W.S., Sidransky, D., Vala, M.S., Akhtar, A.J., Hilton, J. & Jones, R.J. (1995) BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86, 11481158.
  • Chapman, R.S., Whetton, A.D. & Dive, C. (1994) The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase. Cancer Research, 54, 51315137.
  • Chapman, R.S., Whetton, A.D., Chresta, C.M. & Dive, C. (1995) Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Molecular Pharmacology, 48, 334343.
  • Cortez, D., Kadlec, L. & Pendergast, A.M. (1995) Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Molecular and Cellular Biology, 15, 55315541.
  • Cross, N.C., Melo, J.V., Feng, L. & Goldman, J.M. (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia, 8, 186189.
  • Daley, G.Q. & Ben-Neriah, Y. (1991) Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Advances in Cancer Research, 57, 151184.
  • Daley, G.Q., Vanetten, R.A. & Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/Abl gene of the philadelphia-chromosome. Science, 247, 824830.
  • Dierov, J., Dierova, R. & Carroll, M. (2004) BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell, 5, 275285.
  • Eaves, A.C., Cash, J.D., Gaboury, L.A., Kalousek, D.K. & Eaves, D.J. (1986) Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proceedings of the National Academy of Sciences of the United States of America, 83, 53065310.
  • Eaves, C.J., Cashman, J.D., Wolpe, S.D. & Eaves, A.C. (1993) Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proceedings of the National Academy of Sciences of the United States of America, 90, 1201512019.
  • Fialkow, P.J., Gartler, S.M. & Yoshida, A. (1967) Clonal origin of chronic myelocytic leukemia in man. Proceeding of the National Academy of Sciences United States of America, 58, 14681471.
  • Gishizky, M.L. & Witte, O.N. (1992) Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science, 256, 836839.
  • Goldman, J.M. (1997) Chronic myeloid leukemia. Current Opinion in Hematology, 4, 277285.
  • Gordon, M.Y., Dowding, C.R., Riley, G.P., Goldman, J.M. & Greaves, M.F. (1987) Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature, 328, 342344.
  • Hantschel, O., Wiesner, S., Guttler, T., Mackereth, C.D., Rix, L.L.R., Mikes, Z., Dehne, J., Gorlich, D., Sattler, M. & Superti-Furga, G. (2005) Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Molecular Cell, 19, 461473.
  • Heisterkamp, N., Voncken, J.W., Senadheera, D., Gonzalez-Gomez, I., Reichert, A., Haataja, L., Reinikainen, A., Pattengale, P.K. & Groffen, J. (2000) Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood, 96, 22262232.
  • Heyworth, C.M., Dexter, T.M., Kan, O. & Whetton, A.D. (1990) The role of hemopoietic growth factors in self-renewal and differentiation of IL-3-dependent multipotent stem cells. Growth Factors, 2, 197211.
  • Kabarowski, J., Allen, P. & Wiedemann, L. (1994) A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO Journal, 13, 58875895.
  • Kloetzer, W., Kurzrock, R., Smith, L., Talpaz, M., Spiller, M., Gutterman, J. & Arlinghaus, R. (1985) The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology, 140, 230238.
  • Konopka, J.B., Watanabe, S.M. & Witte, O.N. (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 37, 10351042.
  • Kurzrock, R., Gutterman, J.U. & Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 319, 990998.
  • Mayer, B.J., Jackson, P.K., Van Etten, R.A. & Baltimore, D. (1992) Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Molecular and Cellular Biology, 12, 609618.
  • McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. & Cotter, T.G. (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83, 11791187.
  • McLaughlin, J., Chianese, E. & Witte, O.N. (1987) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proceedings of the National Academy of Sciences of the United States of America, 84, 65586562.
  • McWhirter, J.R. & Wang, J.Y. (1991) Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Molecular and Cellular Biology, 11, 15531565.
  • McWhirter, J.R. & Wang, J.Y. (1993) An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO Journal, 12, 15331546.
  • Muller, A.J., Young, J.C., Pendergast, A.M., Pondel, M., Landau, N.R., Littman, D.R. & Witte, O.N. (1991) BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Molecular and Cellular Biology, 11, 17851792.
  • Owen, P.J., Musk, P., Evans, C.A. & Whetton, A.D. (1993) Cellular signaling events elicited by v-abl associated with growth factor independence in an interleukin-3-dependent cell line. Journal of Biological Chemistry, 268, 1569615703.
  • Owen-Lynch, P.J., Wong, A.K. & Whetton, A.D. (1995) v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation. Journal of Biological Chemistry, 270, 59565962.
  • Pierce, A., Owen-Lynch, P.J., Spooncer, E., Dexter, T.M. & Whetton, A.D. (1998) p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene, 17, 667672.
  • Ramaraj, P., Singh, H., Niu, N., Chu, S., Holtz, M., Yee, J.K. & Bhatia, R. (2004) Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Research, 64, 53225331.
  • Renshaw, M.W., McWhirter, J.R. & Wang, J.Y. (1995) The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Molecular and Cellular Biology, 15, 12861293.
  • Rowley, J.D. (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290293.
  • Scherle, P.A., Dorshkind, K. & Witte, O.N. (1990) Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function. Proceedings of the National Academy of Sciences of the United States of America, 87, 19081912.
  • Skourides, P.A., Perera, S.A. & Ren, R. (1999) Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins. Oncogene, 18, 11651176.
  • Spooncer, E., Heyworth, C.M., Dunn, A. & Dexter, T.M. (1986) Self-renewal and differentiation of interleukin-3-dependent multipotent stem cells are modulated by stromal cells and serum factors. Differentiation, 31, 111118.
  • Tauchi, T., Miyazawa, K., Feng, G.S., Broxmeyer, H.E. & Toyama, K. (1997) A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. Journal of Biological Chemistry, 272, 13891394.
  • Van Etten, R.A., Jackson, P. & Baltimore, D. (1989) The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell, 58, 669678.
  • Verfaillie, C.M., McCarthy, J.B. & McGlave, P.B. (1992) Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. Journal of Clinical Investigation, 90, 12321241.
  • Vigneri, P. & Wang, J.Y.J. (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nature Medicine, 7, 228234.
  • Wertheim, J.A., Forsythe, K., Druker, B.J., Hammer, D., Boettiger, D. & Pear, W.S. (2002) BCR-ABL-induced adhesion defects are tyrosine kinase- independent. Blood, 99, 41224130.
  • Wertheim, J.A., Perera, S.A., Hammer, D.A., Ren, R., Boettiger, D. & Pear, W.S. (2003) Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood, 102, 22202228.
  • Wetzler, M., Talpaz, M., Van Etten, R.A., Hirsh-Ginsberg, C., Beran, M. & Kurzrock, R. (1993) Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. Journal of Clinical Investigation, 92, 19251939.
  • Whetton, A.D., Monk, P.N., Consalvey, S.D. & Downes, C.P. (1986) The haemopoietic growth factors interleukin 3 and colony stimulating factor-1 stimulate proliferation but do not induce inositol lipid breakdown in murine bone-marrow-derived macrophages. EMBO Journal, 5, 32813286.
  • Young, J.C. & Witte, O.N. (1988) Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures. Molecular and Cellular Biology, 8, 40794087.